SOFT 2004 Meeting Abstracts - Society of Forensic Toxicologists
SOFT 2004 Meeting Abstracts - Society of Forensic Toxicologists
SOFT 2004 Meeting Abstracts - Society of Forensic Toxicologists
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
M36<br />
EV ALUA TION OF A RAPID ORAL FLUID POINT OF CARE TEST FOR MDMA<br />
Lisa Wilson*, Gail Cooper, Chris Hand and Ahmed lehanli: Cozart Bioscience Ltd., 45 Milton Park,<br />
Abingdon, Oxfordshire, United Kingdom OX144RU<br />
Recreational use <strong>of</strong> 3,4-methylenedioxymethamphetamine (MDMA) either alone or in combination with<br />
other drugs such as alcohol and cannabis has become increasingly popular among young people throughout<br />
the UK, Europe and the US. The Cozart® RapiScan oral fluid drug test system has been use successfully for<br />
monitoring compliance within treatment centres, criminal justice settings and more recently at the roadside.<br />
The aim <strong>of</strong> this study was to evaluate the Cozart® RapiScan test cartridge developed for the detection <strong>of</strong><br />
MDMA and methamphetamine in oral fluid. Fifty oral fluid samples were obtained from drug addicts<br />
attending drug dependency units and were screened initially using the Cozart® microplate ELISA for<br />
amphetamines. All samples were then screened using the Cozart® RapiScan test cartridge for MDMA<br />
followed by confirmation by gas chromatography-mass spectrometry (GC-MS).<br />
A total <strong>of</strong>23 samples screened positive and were confirmed for MDMA either alone or in combination with<br />
amphetamine. A further 15 samples were confirmed negative for all amphetamines by GC-MS and 14 <strong>of</strong><br />
these samples also screened negative using the Cozart® RapiScan. The false positive sample was<br />
investigated further and was found to contain an extremely high concentration <strong>of</strong> pseudoephedrine. The<br />
remaining 12 samples were confirmed positive for amphetamine only. Six samples screened negative and<br />
the other six screened positive due to the extremely high concentrations <strong>of</strong> amphetamine in these samples.<br />
No samples tested in this study contained methamphetamine.<br />
The Cozart® RapiScan Drug Test System for the detection <strong>of</strong> MDMA correctly identified 100% <strong>of</strong> MDMA<br />
~. positive samples ranging from 53nglmL to concentrations in excess <strong>of</strong> lS0ng/mL. False positive results<br />
were only observed when samples contained extremely high concentrations <strong>of</strong> amphetamine or<br />
pseudoephedrine, which is consistent with the cross reactivity pr<strong>of</strong>ile <strong>of</strong> the drug test.<br />
Keywords: MDMA, Oral fluid, Onsite Test<br />
Page 319
Change language